COLUMN

Will Tepid Pricing Debate Only Go Full-Throttle after Golden Week Holidays?

March 30, 2017
Hiroyasu Onishi The ongoing discussions on the proposed drug pricing overhaul appear surprisingly lukewarm. The Ministry of Health, Labor and Welfare (MHLW) opened up discussions by the Central Social Insurance Medical Council’s (Chuikyo) drug pricing subcommittee early this year, but…

To read the full story

COLUMN

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…